| For: | Razok A, Ata F, Ahmed SMI, Al Mohanadi DHSH. Sodium-glucose co-transporter 2 inhibitors induced euglycemic diabetic ketoacidosis within four days of initiation. World J Diabetes 2022; 13(3): 272-274 [PMID: 35432760 DOI: 10.4239/wjd.v13.i3.272] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v13/i3/272.htm |
| Number | Citing Articles |
| 1 |
Jing Cai, Tiantian Fu, Cuixia Tan. Case Report: Early-onset euglycemic diabetic ketoacidosis following henagliflozin initiation in a treatment-naive patient. Frontiers in Endocrinology 2026; 17 doi: 10.3389/fendo.2026.1882272
|
| 2 |
Yiwei Huang, Xinyuan Yu, Changxin Li. Sodium–Glucose Cotransporter 2 Inhibitors: An Emerging Therapeutic Approach for Ischemic Stroke Management. CNS Drugs 2025; 39(12) doi: 10.1007/s40263-025-01230-3
|
| 3 |
Dora Cerovec, Ana Marija Slišković, Ivana Sopek Merkaš, Nenad Lakušić. Euglycemic diabetic ketoacidosis: A rare but serious side effect of sodium-glucose co-transporter 2 inhibitors. World Journal of Cardiology 2022; 14(10): 561-564 doi: 10.4330/wjc.v14.i10.561
|
| 4 |
|